India, Oct. 21 -- Achieve Life Sciences (ACHV) presented new 52-week results from its ORCA-OL clinical trial showing that extended treatment with cytisinicline helped a meaningful proportion of participants quit smoking or vaping, including individuals who had previously failed a medically supported quit attempt.
The open-label trial enrolled 479 adults, with 475 receiving at least one dose of cytisinicline 3 mg three times daily for up to 52 weeks, alongside behavioral support.
Four-week sustained abstinence during the final four weeks of treatment reached 31.2% across the study population, including 32.8% of participants who exclusively smoked and 24.6% of those who exclusively vaped.
Among participants who had received placebo in an e...